Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab plus Lenalidomide for Multiple Myeloma Serologic Relapse
NCT03411031Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Started Oct 2018; status: terminated.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03411031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411031.